One study demonstrated that the antitumor effects of the multi-kinase inhibitor sorafenib, the Feline McDonough Sarcoma-like tyrosine kinase 3 (FLT3) inhibitor quizartinib, and the bifunctional FLT3 plus cyclin-dependent kinases 4 and 6 inhibitor AMG925 in subcutaneous and orthotopic mouse models of acute myeloid leukemia could be described well by the Simeoni model [104]. The gene discussed is FLT3; the disease is acute myeloid leukemia.